LONDON – 18 August 2026 — CHARM Therapeutics (“CHARM”, “The Company”), a biotechnology company addressing resistance in acute myeloid leukemia (AML) with a best-in-class menin inhibitor, announces the formation of its Clinical Advisory Boar…
If you are dissatisfied with how your personal data has been handled, you have the right to raise a complaint about how we have collected, used, shared or responded to your data. Please complete the form below before clicking ‘submit’. All
Menin inhibitors have emerged as a clinically validated therapeutic class for the treatment of acute AML. However, first-generation inhibitors are limited by the rapid emergence of resistance mutations in menin that reduce efficacy and lead…
As Chief Medical Officer, Erkut will lead clinical development strategy and execution as CHARM advances its lead menin inhibitor, a potential new treatment for acute myeloid leukemia (AML), toward first-in-human studies, with clinical devel…
CHARM’s next generation menin inhibitors Acute myeloid leukemia (AML) is a rapidly progressing and aggressive blood cancer with poor prognosis for many patients. Menin inhibitors have recently emerged as a clinically-validated therapeutic c…
She recently served as Chief Executive Officer at Zentalis Pharmaceuticals (2022-2024) and holds educational credentials from Duke University, including a Bachelor’s degree in Bioethics/Medical Ethics and completion of the Medical Oncology
His executive leadership experience spans senior roles across major pharmaceutical companies, including CEO of Syndax Pharmaceuticals, Head of Clinical Development at Pfizer, and Head of Global Medicines Development and Chief Medical Office…
He holds dual degrees from the University of Cambridge (MA, Medical & Natural Sciences, Starred 1st Class) and University College London (MBBS, Medicine, Distinction), and is a Fellow of the Faculty of Pharmaceutical Medicine with specialis…
He brings unique dual expertise as both a practicing physician (M.D. from University of Illinois College of Medicine) and MBA graduate from The University of Chicago Booth School of Business, where he specialized in Strategy, Finance, and E…
Prior to NEA, James held positions at SR One Capital Management, Morgan Stanley, and New Rhein Healthcare Investors. He began his career as first a physician and then a cardiothoracic surgeon. James received a BSc in surgical and medical sc…
Acute myeloid leukemia (AML) is a rapidly progressing and aggressive cancer of the blood and bone marrow characterized by the uncontrolled growth of abnormal myeloid cells that fail to mature properly. Despite advances in targeted therapies…
Prior to founding CHARM, he was a core contributor at Exscientia (NASDAQ:EXAI), a leading AI drug discovery company, where he worked on their machine learning platform. Laksh started his entrepreneurship journey as an undergraduate, co-foun…